]>
IRCT20091108002680N3 IRCT 2020-02-24 Rasht University of Medical Sciences Assessment of the effect of nano-curcumin oral intake on clinical signs and serum IL-6 levels in patients with ischemic stroke: Double-blind Clinical Trial Assessment of the effect of nano-curcumin oral intake on clinical signs and serum IL-6 levels in patients with ischemic stroke: Double-blind Clinical Trial 2020-04-20 anticipated 40 Complete https://irct.ir/trial/41485 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Blocked randomization is used for randomization.The blocks are fixed and 4 in size that the first 2 will be in the curcumin group and the second 2 will be in the placebo group, Blinding description: Individuals under study, physicians and those assessing outcomes are kept blind to specific study groups. After selecting patients, medications are given to patients in unnamed and similar envelopes by Ms. Samaneh Shirkoohi, and the list of patients in each group will not be disclosed until the end of the data analysis. 3 Ischemic cerebral stroke. Intervention 1: Intervention group: capsule nano-curcumin (sina curcumin) 80 mg Daily for 1 month. Intervention 2: Control group: Capsules containing polycarbate 80 are quite similar to the main drug Daily for 1 month. Yes - There is a plan to make this available What will be shared: After the end of the study period When: After the end of the study period To whom: Once the results are published as an article, they will be made public Conditions: If published as an article Where to obtain: Guilan University of Medical Sciences Neuroscience Research Center How to obtain: Visiting to Neuroscience Research Center of Guilan University of Medical Sciences Comments:
public Doctor Alia Saberi
Neuroscience Research Center, Pursina Hospital, Nursing Street
Rasht Iran (Islamic Republic of) 41937-13194 +98 13 3332 2444 a_saberi@gums.ac.ir Rasht University of Medical Sciences scientific Doctor Alia Saberi
Neuroscience Research Center, Pursina Hospital, Nursing Street
Rasht Iran (Islamic Republic of) 41937-13194 +98 13 3332 2444 a_saberi@gums.ac.ir Rasht University of Medical Sciences Iran (Islamic Republic of) Ischemic CVA less than 1 week from their symptoms begin National Institutes of Health Stroke Scale (NIHSS) <= 20 Modified Rankin Scale (MRS) <= 4 no limit no limit Both Cerebral Venous Thrombosis Hemorrhagic infarction Internal capsule and Middle Cerebral Artery trunk infarction History of gall bladder stone or bile duct stenosis Gastroesophageal reflux disease or active peptic ulcer Use of NSAIDs or Reserpine Using anticoagulant or thrombolitic agent in last 24 hours Using of Warfarin in last 1 week Dissatisfaction More than 1 week from symptoms begin I64 Stroke, non specified as haemorrhage or infarction Treatment - Drugs Placebo Intervention group: capsule nano-curcumin (sina curcumin) 80 mg Daily for 1 month Control group: Capsules containing polycarbate 80 are quite similar to the main drug Daily for 1 month Blood levels of inflammatory factor interleukin-6. Timepoint: Before treatment and after 1 month. Method of measurement: ELISA kit. Rasht University of Medical Sciences Approved 2019-08-03 Ethics committee of gilan University of Medical Sciences Neuroscience Research Center, Pursina Hospital, Nursing Street rasht Guilan Iran (Islamic Republic of)